Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 (NCT03785249)

🧪 Interventions in This Study

• MRTX849 (DRUG)
• Pembrolizumab (DRUG)
• Cetuximab (DRUG)
• Afatinib (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (222 Sites)

Showing the first 25 of 222 sites.

• Local Institution - 001-826 — Birmingham, Alabama
• Local Institution - 001-965 — Anchorage, Alaska
• Local Institution - 001-821 — Phoenix, Arizona
• Local Institution - 001-873-A — Tucson, Arizona
• Local Institution - 001-873 — Tucson, Arizona
• Local Institution - 001-840-B — Bellflower, California
• Local Institution - 001-834 — Beverly Hills, California
• Local Institution - 001-843 — Duarte, California
• Local Institution - 001-850-K — Dublin, California
• Local Institution - 001-851 — Fullerton, California
• Local Institution - 001-840-C — Harbor City, California
• Local Institution - 001-805 — La Jolla, California
• Local Institution - 001-779 — Los Alamitos, California
• Local Institution - 001-840 — Los Angeles, California
• Local Institution - 001-578 — Los Angeles, California
• Local Institution - 001-847 — Newport Beach, California
• Local Institution - 001-850-B — Oakland, California
• Local Institution - 001-803 — Orange, California
• Local Institution - 001-850-C — Roseville, California
• Local Institution - 001-850-J — Sacramento, California
• Local Institution - 001-850-D — Sacramento, California
• Local Institution - 001-845 — San Diego, California
• Local Institution - 001-840-A — San Diego, California
• Local Institution - 001-850-H — San Francisco, California
• Local Institution - 001-850-E — San Francisco, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Cancer

• Intrapleural Catheter Daily Versus Three Times a Week Drainage — Houston, Texas
• Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer — Toronto, Ontario
• Meaning-Centered Intervention for Muslim Patients Who Are Being Treated for Advanced Cancer — New York, New York
• FS120 Phase 1/1b Study in Patients With Advanced Malignancies — New Haven, Connecticut
• First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer — Encinitas, California
• Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21) — Santa Rosa, California

Explore by condition: All Advanced Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.